Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment.

Although the chemotherapy benefit in women ≤50 years was modest (5%), it remained clinically meaningful and approached significance with longer follow-up.

also in 8,237 other papers

In TAILORx, among patients receiving chemotherapy, those with Oncotype DX RS≥31 experienced superior DRFI/DRFS/RFS with T-AC versus TC and showed a trend toward improved OS; benefit increased incrementally with higher RS scores when analyzed as a continuous variable, whereas no benefit was observed for patients with RS <31 ( 3 ).

also in 53,322 other papers